- Home
- CORT vs ESAB Comparison
CORT vs ESAB Comparison
Compare CORT & ESAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CORT | ESAB |
|---|---|---|
| Founded | 1998 | 1904 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Office Equipment/Supplies/Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 5.6B |
| IPO Year | 2001 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CORT | ESAB |
|---|---|---|
| Price | $112.94 | $67.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $96.50 | ★ $138.56 |
| AVG Volume (30 Days) | ★ 842.6K | 769.8K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.42% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.09 | ★ 1.27 |
| Revenue | $761,407,000.00 | ★ $2,842,555,000.00 |
| Revenue This Year | $26.08 | $6.21 |
| Revenue Next Year | $26.98 | $5.33 |
| P/E Ratio | $1,305.61 | ★ $53.89 |
| Revenue Growth | ★ 12.79 | 3.71 |
| 52 Week Low | $28.66 | $64.86 |
| 52 Week High | $126.38 | $137.42 |
Technical Indicators
Market Signals| Indicator | CORT | ESAB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2025.